MedTrace Logo

Antistaphylococcal Betalactam and Emergence of Resistance

NCT05939479 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 644

Last updated 2025-08-08

No results posted yet for this study

Summary

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

Conditions

  • Bacterial Resistance
  • Methicillin-Sensitive Staphylococcus Aureus Infection

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-05-01
Completion
2023-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05939479 on ClinicalTrials.gov